Majima Tokifumi, Inoue Masahiro, Kasahara Yasuhiko, Onodera Tomohiro, Takahashi Daisuke, Minami Akio
Department of Joint Replacement and Tissue Engineering, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
Sports Med Arthrosc Rehabil Ther Technol. 2012 Jan 10;4:3. doi: 10.1186/1758-2555-4-3.
Boiogito (Japanese herbal medicine, Tsumura Co. Tokyo, Japan) contains sinomenin which inhibits inflammatory reactions. Since sinomenine is a principle component of the Boiogito, there is a possibility of it being effective on osteoarthritis (OA) of the knee with joint effusion. However, there is no report concerning the effectiveness of Boiogito on knee OA. The objective of the present study is to investigate the therapeutic effect of Boiogito on OA of the knee associated with joint effusion in a comparative study among randomly assigned groups.
Study was performed using 50 patients who were diagnosed with primary osteoarthritis of the knee with joint effusion. The patients were randomly assigned to two groups: one group (25 patients) using both loxoprofen (2-{4-[(2-oxocyclopentyl) methyl]} propanoic acid) and Boiogito and the other group (25 patients) using loxoprofen, and were evaluated during a 12 week observation period. The assessment parameters including knee scores in the Knee Society Rating System including Knee score and Functional scores, amount of joint effusion by joint puncture in clinically detected cases, the 36-items short form of the Medical Outcome Study Questionnaire (SF-36) as a measurement of health related quality of life were used.
The knee scores based on the Knee Society Rating System were improved in both groups. The staircase climbing up and down ability in the Knee society rating system functional score was significantly improved in the group using Boiogito and loxoprofen compared to the loxoprofen group. In the evaluation using SF-36, significant improvements were found in the scores in both groups in physical functioning after 12 weeks. The amount of joint fluid was significantly decreased at 4, 8 and 12 weeks compared to pre-administration baseline in the group using Boiogito and loxoprofen. A side effect of Boiogito, dry mouth, was found in one case. The symptom was mild and improved immediately after discontinuation of administration.
The results indicated that Boiogito have a possibility for a treatment modality for joint effusion with osteoarthritis of the knee.
Boiogito（日本草药，日本东京津村公司）含有抑制炎症反应的青藤碱。由于青藤碱是Boiogito的主要成分，它有可能对伴有关节积液的膝骨关节炎（OA）有效。然而，尚无关于Boiogito对膝骨关节炎有效性的报道。本研究的目的是在随机分组的比较研究中，探讨Boiogito对伴有关节积液的膝骨关节炎的治疗效果。
对50例诊断为原发性膝骨关节炎伴关节积液的患者进行研究。患者被随机分为两组：一组（25例）使用洛索洛芬（2-{4-[(2-氧代环戊基)甲基]}丙酸）和Boiogito，另一组（25例）仅使用洛索洛芬，并在12周的观察期内进行评估。评估参数包括膝关节协会评分系统中的膝关节评分，包括膝关节评分和功能评分；临床检测病例中通过关节穿刺的关节积液量；作为健康相关生活质量衡量指标的医学结局研究问卷简表36项（SF-36）。
两组基于膝关节协会评分系统的膝关节评分均有所改善。与仅使用洛索洛芬的组相比，使用Boiogito和洛索洛芬的组在膝关节协会评分系统功能评分中的上下楼梯能力有显著改善。在使用SF-36的评估中，12周后两组的身体功能评分均有显著提高。与使用Boiogito和洛索洛芬组给药前的基线相比，在第4、8和12周时关节液量显著减少。发现1例Boiogito的副作用——口干。症状轻微，停药后立即改善。
结果表明，Boiogito有可能成为治疗膝骨关节炎伴关节积液的一种治疗方式。
Zotero 插件
